DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ABBOTT INDIA LIMITED (ABBOTINDIA) share price today?

ABBOTT INDIA LIMITED (ABBOTINDIA) is trading at ₹28,055 on the NSE, up 0.66% on the day. Source: DocStoX.

What is the PE ratio of ABBOTT INDIA LIMITED?

ABBOTT INDIA LIMITED has a price-to-earnings (PE) ratio of 42.1 in the Healthcare sector.

What is the market capitalisation of ABBOTT INDIA LIMITED?

ABBOTT INDIA LIMITED has a market capitalisation of approximately ₹59,614 crore.

ABBOTT INDIA LIMITED

ABBOTINDIA·NSE·Healthcare

₹28,055.00▲ +185.00 (+0.66%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

NIFTY 500NIFTY MIDCAP 150NIFTY PHARMA

Day₹27445.00

₹28170.00

52W₹25150

₹3531029%

Open

₹27920.00

High

₹28170.00

Low

₹27445.00

Prev Close

₹27870.00

Volume

11.1K

VWAP

₹27826.93

Snapshot

Key fundamentals

Market Cap

₹59,614 Cr

P/E Ratio

42.15Expensive

P/B Ratio

11.45

EPS

₹665.64

Book Value

₹2246.68

ROE

33.41%Strong

ROCE

46.00%Efficient

Dividend Yield

2.45%

Debt / Equity

0.04Low

Face Value

₹10.00

52W High

₹35310.00

52W Low

₹25150.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹4,457

▼ 84.1%downside

Trading at ₹28,055 — 84% above our estimate

BearFair valueBull

₹3,789₹4,457₹5,801

/100

Business quality — Solid

Growth 0Profitability 100Efficiency 50Valuation 59

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Revenue has been shrinking

Strengths

Virtually debt-free balance sheet
Strong returns on equity (33%)
Capital is working hard (ROCE 46%)
Promoters hold a controlling stake

Risks

Revenue has been shrinking
Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

33% ROE fading to 12% over ~10 yrs, on ₹2247 book

₹4,084

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹5,801

Analyst target

No analyst coverage

—

Blended fair value₹4,457

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Strong returns on equity (33%)
Capital is working hard (ROCE 46%)
Promoters hold a controlling stake

Bear case

Revenue has been shrinking
Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

42.1Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

33.4%Strong

Above 15% is considered healthy for Indian equities

ROCE

46.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.04Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹59,614 Cr

P/B

11.45

EPS

₹665.64

Div Yield

2.45%

What changed

Recent changes

Foreign investors+0.1% stake last quarter
Domestic institutions-0.2% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 42.1×

Growth

Steady

+9% rev CAGR

Profitability

Excellent

33.4% ROE

Financial health

Rock solid

D/E 0.04

Momentum

N/A

No technicals

Today

Trading activity

Delivery %56.2%

Turnover₹3088.79L Cr

Trades4,975

VWAP₹27826.93

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+9.0%

+10.0%

10Y

+10.2%

Profit

+17.8%

+17.6%

10Y

+19.8%

EPS

—

10Y

—

Profile

Pros

Company is almost debt free.
Company has a good return on equity (ROE) track record: 3 Years ROE 35.0%
Company has been maintaining a healthy dividend payout of 69.6%

Watch-outs

Cons

Stock is trading at 12.1 times its book value
The company has delivered a poor sales growth of 9.96% over past five years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors bought 0.11 pts; domestic institutions reduced 0.16 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

75%

Promoter

Promoters

75.0%0.00

Public

15.8%+0.04

FII / FPI

0.4%+0.11

DII

8.8%-0.16

Quarterly trend

Ownership over time

Q1 FY27

Promoter74.99%

FII0.38%

DII8.77%

Public15.85%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions